These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15317823)

  • 1. Ibandronate: a clinical pharmacological and pharmacokinetic update.
    Barrett J; Worth E; Bauss F; Epstein S
    J Clin Pharmacol; 2004 Sep; 44(9):951-65. PubMed ID: 15317823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
    Guay DR
    Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ibandronate given by intravenous injection once every 3 months.
    Adami S; Felsenberg D; Christiansen C; Robinson J; Lorenc RS; Mahoney P; Coutant K; Schimmer RC; Delmas PD
    Bone; 2004 May; 34(5):881-9. PubMed ID: 15121020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.
    Bauss F; Russell RG
    Osteoporos Int; 2004 Jun; 15(6):423-33. PubMed ID: 15205712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate.
    Ringe JD; Dorst A; Faber H
    Osteoporos Int; 2005 Dec; 16(12):2063-8. PubMed ID: 16228105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis.
    Papapoulos SE
    Int J Clin Pract; 2003 Jun; 57(5):417-22. PubMed ID: 12846348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.
    Pillai G; Gieschke R; Goggin T; Jacqmin P; Schimmer RC; Steimer JL
    Br J Clin Pharmacol; 2004 Dec; 58(6):618-31. PubMed ID: 15563360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
    Eisman JA; Civitelli R; Adami S; Czerwinski E; Recknor C; Prince R; Reginster JY; Zaidi M; Felsenberg D; Hughes C; Mairon N; Masanauskaite D; Reid DM; Delmas PD; Recker RR
    J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females.
    Pillai G; Gieschke R; Goggin T; Barrett J; Worth E; Steimer JL
    Int J Clin Pharmacol Ther; 2006 Dec; 44(12):655-67. PubMed ID: 17190376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
    Recker R; Stakkestad JA; Chesnut CH; Christiansen C; Skag A; Hoiseth A; Ettinger M; Mahoney P; Schimmer RC; Delmas PD
    Bone; 2004 May; 34(5):890-9. PubMed ID: 15121021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis.
    Schlosser K; Scigalla P
    Scand J Clin Lab Invest Suppl; 1997; 227():21-8. PubMed ID: 9127465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.
    Ringe JD; Dorst A; Faber H; Ibach K; Preuss J
    Rheumatology (Oxford); 2003 Jun; 42(6):743-9. PubMed ID: 12730532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibandronate.
    Dooley M; Balfour JA
    Drugs; 1999 Jan; 57(1):101-8; discussion 109-10. PubMed ID: 9951955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibandronate: new options in the treatment of osteoporosis.
    Adami S; Viapiana O
    Drugs Today (Barc); 2003 Nov; 39(11):877-86. PubMed ID: 14702133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic agents for disorders of bone and calcium metabolism: Ibandronate].
    Hashimoto J
    Clin Calcium; 2007 Jan; 17(1):11-7. PubMed ID: 17211088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties.
    Nakai K; Tobinai M; Hashimoto J; Iida S; Kawanishi T
    Eur J Drug Metab Pharmacokinet; 2016 Apr; 41(2):139-47. PubMed ID: 25476995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection.
    Pecherstorfer M; Ludwig H; Schlosser K; Buck S; Huss HJ; Body JJ
    J Bone Miner Res; 1996 May; 11(5):587-93. PubMed ID: 9157773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.
    Reginster JY; Wilson KM; Dumont E; Bonvoisin B; Barrett J
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5018-24. PubMed ID: 15972582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.
    Heidenreich A; Ohlmann CH
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):991-1005. PubMed ID: 15606328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.